Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SLS
- Price
- 1.54
- Stock movement down
- -0.09 (-4.86%)
- Company name
- Sellas Life Sciences Group Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 185.32M
- Ent value
- 174.90M
- Price/Sales
- -
- Price/Book
- 11.66
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -58.24%
- 1 year return
- 26.62%
- 3 year return
- -17.72%
- 5 year return
- -9.63%
- 10 year return
- -63.71%
Last updated: 2025-09-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
SLS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 11.66 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 105.30M |
| EPS (TTM) | -0.47 |
| FCF per share (TTM) | -0.57 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -32.77M |
| Net income (TTM) | -32.28M |
| EPS (TTM) | -0.47 |
| EPS (1y forward) | -0.36 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 21.03M |
| Net receivables | 0.00 |
| Total current assets | 24.04M |
| Goodwill | 1.91M |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 26.50M |
| Accounts payable | 4.55M |
| Short/Current long term debt | 576.00K |
| Total current liabilities | 10.61M |
| Total liabilities | 10.61M |
| Shareholder's equity | 15.89M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -33.07M |
| Capital expenditures (TTM) | 5.50M |
| Free cash flow (TTM) | -38.57M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -203.12% |
| Return on Assets | -121.79% |
| Return on Invested Capital | -196.02% |
| Cash Return on Invested Capital | -234.24% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.89 |
| Daily high | 1.90 |
| Daily low | 1.75 |
| Daily Volume | 1.70M |
| All-time high | 335364.00 |
| 1y analyst estimate | 6.83 |
| Beta | 2.27 |
| EPS (TTM) | -0.47 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 Nov 2025 |
Downside potential
Loading...
Downside potential data
| SLS | S&P500 | |
| Current price drop from All-time high | -100.00% | -1.46% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 20 Feb 2024 | 9 Mar 2009 |
| Avg drop from high | -88.95% | -10.99% |
| Avg time to new high | 2195 days | 12 days |
| Max time to new high | 4389 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
185.32M
Marketcap category
Small-cap
Description
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Employees
15
Investor relations
-
SEC filings
CEO
Angelos M. Stergiou
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page